8-K current report · filed Oct 5, 2026

Korro Bio, Inc. (KRRO) 8-K Current Report: October 5, 2026

Item 8.01Item EX-99.1KRRO overview

Short answer

Korro Bio, Inc. (KRRO) filed an 8-K current report with the SEC on October 5, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). First ANCHOR cohort dosed, advancing KRRO-121 into Phase 1/2 clinical testing.

Korro Bio, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • First ANCHOR cohort dosed, advancing KRRO-121 into Phase 1/2 clinical testing
  • KRRO-121 targets hyperammonemia in urea cycle disorders and hepatic encephalopathy
  • Clinical progress creates a potential catalyst, with future readouts driving efficacy and safety assessment
  • Exhibit 99.1 contains the company’s supporting press release

Item EX-99.1 · Exhibit EX-99.1

  • First cohort dosed in Phase 1/2 ANCHOR trial, advancing KRRO-121 from preclinical testing into human safety evaluation
  • Single 2mg/kg dose administered to healthy volunteers, with placebo-controlled SAD and MAD studies planned for up to 50 participants
  • UCD patient dosing expected in first half of 2027, with interim clinical readout expected in second half of 2027
  • Phase 2 plans up to 15 UCD participants across all genotypes, supporting KRRO-121’s potential pan-UCD positioning
  • Clinical validation now becomes the key catalyst, with safety, pharmacokinetics and ammonia-control activity determining program value

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Korro Bio, Inc. 8-K filings

Get the next KRRO 8-K as it lands

Follow KRRO for push alerts, or ask the research agent what this filing means.